A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Orciprenaline
Azidocillin
The therapeutic efficacy of Tubocurarine can be increased when used in combination with Azidocillin.
Orciprenaline
Ticarcillin
The therapeutic efficacy of Tubocurarine can be increased when used in combination with Ticarcillin.
Orciprenaline
Pivmecillinam
The therapeutic efficacy of Tubocurarine can be increased when used in combination with Pivmecillinam.
Orciprenaline
Pivampicillin
The therapeutic efficacy of Tubocurarine can be increased when used in combination with Pivampicillin.
Orciprenaline
Meticillin
The therapeutic efficacy of Tubocurarine can be increased when used in combination with Meticillin.
Orciprenaline
Bacampicillin
The therapeutic efficacy of Tubocurarine can be increased when used in combination with Bacampicillin.
Orciprenaline
Amdinocillin
The therapeutic efficacy of Tubocurarine can be increased when used in combination with Amdinocillin.
Orciprenaline
Azlocillin
The therapeutic efficacy of Tubocurarine can be increased when used in combination with Azlocillin.
Orciprenaline
Mezlocillin
The therapeutic efficacy of Tubocurarine can be increased when used in combination with Mezlocillin.
Orciprenaline
Benzylpenicilloyl polylysine
The therapeutic efficacy of Tubocurarine can be increased when used in combination with Benzylpenicilloyl polylysine.
Orciprenaline
Dronedarone
The risk or severity of adverse effects can be increased when Dronedarone is combined with Tubocurarine.
Orciprenaline
Choline salicylate
The risk or severity of adverse effects can be increased when Choline salicylate is combined with Tubocurarine.
Orciprenaline
Estradiol valerate
The risk or severity of adverse effects can be increased when Estradiol valerate is combined with Tubocurarine.
Orciprenaline
Estradiol dienanthate
The risk or severity of adverse effects can be increased when Estradiol dienanthate is combined with Tubocurarine.
Orciprenaline
Estradiol cypionate
The risk or severity of adverse effects can be increased when Estradiol cypionate is combined with Tubocurarine.
Orciprenaline
Estradiol benzoate
The risk or severity of adverse effects can be increased when Estradiol benzoate is combined with Tubocurarine.
Orciprenaline
Estradiol acetate
The risk or severity of adverse effects can be increased when Estradiol acetate is combined with Tubocurarine.
Orciprenaline
Rucaparib
The risk or severity of adverse effects can be increased when Rucaparib is combined with Tubocurarine.
Orciprenaline
Gilteritinib
The risk or severity of adverse effects can be increased when Gilteritinib is combined with Tubocurarine.
Orciprenaline
Dacomitinib
The risk or severity of adverse effects can be increased when Dacomitinib is combined with Tubocurarine.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3